Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Search terms for systematic review, by database.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • معلومة اضافية
    • الموضوع:
      2024
    • نبذة مختصرة :
      Background Historically, lack of data on cost-effectiveness of influenza vaccination has been identified as a barrier to vaccine use in low- and middle-income countries. We conducted a systematic review of economic evaluations describing (1) costs of influenza illness; (2) costs of influenza vaccination programs; and (3) vaccination cost-effectiveness from low- and middle-income countries to assess if gaps persist that could hinder global implementation of influenza vaccination programs. Methods and findings We performed a systematic search in Medline, Embase, Cochrane Library, CINAHL, and Scopus in January 2022 and October 2023 using a combination of the following key words: “influenza” AND “cost” OR “economic.” The search included studies with publication years 2012 through 2022. Studies were eligible if they (1) presented original, peer-reviewed findings on cost of illness, cost of vaccination program, or cost-effectiveness of vaccination for seasonal influenza; and (2) included data for at least 1 low- or middle-income country. We abstracted general study characteristics and data specific to each of the 3 study types. Of 54 included studies, 26 presented data on cost-effectiveness, 24 on cost-of-illness, and 5 on program costs. Represented countries were classified as upper-middle income (UMIC; n = 12), lower-middle income (LMIC; n = 7), and low-income (LIC; n = 3). The most evaluated target groups were children ( n = 26 studies), older adults ( n = 17), and persons with chronic medical conditions ( n = 12); fewer studies evaluated pregnant persons ( n = 9), healthcare workers ( n = 5), and persons in congregate living settings ( n = 1). Costs-of-illness were generally higher in UMICs than in LMICs/LICs; however, the highest national economic burden, as a percent of gross domestic product and national health expenditure, was reported from an LIC. Among studies that evaluated the cost-effectiveness of influenza vaccine introduction, most (88%) interpreted at least 1 scenario per target group as either ...
    • Relation:
      https://figshare.com/articles/journal_contribution/Search_terms_for_systematic_review_by_database_/24951876
    • الرقم المعرف:
      10.1371/journal.pmed.1004333.s004
    • Rights:
      CC BY 4.0
    • الرقم المعرف:
      edsbas.83E85E63